

CURRICULUM VITAE

Peter P. Lee, M.D.

Billy Wilder Endowed Professor and Chair
City of Hope/Beckman Research Institute
1500 East Duarte Road
Duarte, CA 91010
626.218.2519, plee@coh.org
Fax: 626.301.8817
Date Prepared: May 2025

I. EDUCATION

College or University University of California Los Angeles, Los Angeles, CA, B.S., Microbiology, 1985

Medical School University of California San Diego, San Diego, CA, M.D., 1989

II. POST GRADUATE EDUCATION AND TRAINING

Residency Scripps Clinic (Internal Medicine), La Jolla, CA, 01/1989 – 12/1992

Fellowship University of California, San Francisco (Immunology and Allergy), San Francisco, CA,
01/1992 – 12/1994

Research Fellowship University of California, San Francisco (Immunogenetics and Transplantation),
San Francisco, CA, 01/1993 – 12/1994

Fellowship Stanford University, (Hematology), Stanford, CA, 01/1995 – 12/1999

CERTIFICATIONS

- 1992 - American Board of Internal Medicine
- 1995 - American Board of Allergy and Immunology

MEDICAL LICENSURES (if applicable)

- 1990 – 2026 California Medical License G70263 (active)

- 2012 – 2021 United States Department of Justice Drug Enforcement Administration BL2543800 (active)

III. PROFESSIONAL EXPERIENCE, POSITIONS & EMPLOYMENT

1999 – 2006 Assistant Professor of Medicine (Hematology), Stanford University

2006 – 2011 Associate Professor of Medicine (with tenure), Stanford University

2011 – 2013 Professor and Associate Chair, Cancer Immunotherapeutics and Tumor Immunology (CITI),
City of Hope Comprehensive Cancer Center

2013 – Billy Wilder Endowed Professor and Chair, Department of Immuno-Oncology, City of Hope
Comprehensive Cancer Center

IV. NATIONAL HONORS, SCHOLARSHIPS AND AWARDS HONORS AND AWARDS

1985 Magna Cum Laude, Phi Beta Kappa, Departmental and College Honors, UCLA

1986 NIH Summer Research Fellowship

1992 Gordon Shultz Award for Outstanding Research, Scripps Clinic

1994 Outstanding Young Investigator, World Transplantation Society

2001 Stanford Medical School Excellence in Teaching

2001 – 2004 Damon Runyon Scholar Award (Connie and Bob Lurie Scholar)

2003 – 2007 American Cancer Society (ACS) Research Scholar

2006 Elected member, American Society for Clinical Investigation (ASCI)

2006 – 2011 Department of Defense Era of Hope Scholar Award for Breast Cancer Research

2012 – 2017 Department of Defense Era of Hope Expansion Award for Breast Cancer Research

2015 – 2019 Leader, Stand Up to Cancer (SU2C) Convergence Team

2023 Inductee, Asian American Hall of Fame

V. CLINICAL ACTIVITIES

2011 Physician, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope

VI. SERVICE TO PROFESSION

NIH Study Section NIH Study Sections (Ad Hoc member)

NIH/NCI Program Projects, SPORC, Cancer Center Review

Editorial Boards	Editorial Board Member, Hematologist, Cancer Immunology Research
Journal Reviews	Nature Medicine, New England Journal of Medicine, PLoS Medicine, PNAS, J Exp Med, PLoS Biology, Nature Methods, Cancer Research, Blood, Clinical Cancer Research, Journal of Immunotherapy, Immunology Today, Cancer Letters, Human Immunology, British J Cancer
Grant Reviews	DoD BCRP Integration Panel (Ad Hoc member) ACS LIB review panel (Ad Hoc member) European Commission (EC) Programme for Research, Cancer Research UK, Singapore Scientific Counsel
Symposia	Scientific Program Committee (SPC), Society for Immunotherapy of Cancer (SITC)

VII. GRANTS/RESEARCH SUPPORT

ACTIVE GRANTS

- 09/01/2024 – 08/30/26 10063276
- Colorectal Cancer Alliance
- Project Cure CRC grant
- \$1,000,000
- Principal Investigator
- 06/01/2023 – 11/30/27 5 P30 CA33572
- National Institutes of Health/National Cancer Institute
- Cancer Center Support Grant
- \$18,510,638
- Program Leader
- 09/20/23 – 08/31/28 U01 CA286808-01
- National Institutes of Health/National Cancer Institute Center
- A Prospective Cohort Study of Patients with Non-Small Cell Lung Cancer and Multiple Myeloma to Assess the Benefits and Harms Related to Cannabis Use During Treatment
- \$3,037,070
- Co-Investigator

PENDING GRANTS/RESEARCH SUPPORT

- 07/01/24 – 06/30/27 BC231142
- Department of the Army
- Exhausted T cells as a novel biomarker for early-stage premenopausal ER+HER2- breast cancer
- \$1,937,961
- Principal Investigator

COMPLETED GRANTS/RESEARCH SUPPORT

- 09/16/19 – 08/31/24 U01 CA232216

- National Institutes of Health/National Cancer Institute Center
- Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer
- \$3,123,980
- Principal Investigator
- 02/01/22 – 01/31/25 W81XWWH2210031
- Department of Defense
- Repurposing Antiparasitic Drug Ivermectin for Combination Immunotherapy to Combat Metastatic Breast Cancer
- \$1,759,998
- Principal Investigator
- 09/01/23 – 08/31/24 (no number provided)
- Wendy Walk Foundation
- Deciphering the local and systemic immune response in retroperitoneal liposarcoma: can we develop patient immunity
- \$40,000
- Co-Investigator
- 03/15/19 – 02/29/24 R01 CA229510
- National Institutes of Health/National Cancer Institute Center
- Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy
- \$2,836,531
- Co-Investigator
- 01/01/20 – 12/31/22
- The Norman and Sadie Lee Foundation
- Development of a Novel Immunotherapy for Breast and Gastrointestinal Cancer
- \$150,000
- Principal Investigator
- 11/01/20 – 10/31/21
- Cancer Prevention Initiative
- Immune Chemoprevention for Breast Cancer via Repurposing a Low-Cost, Safe Anti-parasitic Drug
- \$150,000
- Principal Investigator
- 01/01/20 – 06/01/21
- Breast Cancer Research Foundation
- Ecology of the Tumor Microenvironment in Breast Cancer
- \$117,000
- Principal Investigator
- 03/01/19 – 02/28/21
- HeritX
- Immuno-Chemoprevention for Breast Cancer

- \$150,000
- Principal Investigator
- 03/01/19 – 02/28/21
- MD Anderson
- Uncovering Mutant TP53 Dependencies in Spontaneously-Arising Triple-Negative Breast Cancers
- Principal Investigator
- 06/1/15 – 06/30/20
- Stand Up To Cancer
- Ecology of the Tumor Microenvironment in Breast Cancer
- Principal Investigator
- 009/30/12 – 08/31/17 W81XWH-12-1-0366 BC112729
- Department of Defense Era of Hope
- Integrated Immunotherapy for Breast Cancer
- Principal Investigator
- 09/30/12 – 08/31/17
- Integrated Immunotherapy for Breast Cancer
- Principal Investigator
- 04/01/12 – 09/24/16 W81XWH-11-1-0548
- Enhancing the Breadth and Efficacy of Therapeutic Vaccines for Breast Cancer
- Principal Investigator
- 01/01/08 – 12/31/15 R01 CA130817
- Interplay Between Cancer and Immune Cells on Targeted Therapy
- Principal Investigator
- 07/01/07 – 04/30/14 R01 CA127947
- Immune Profile Analysis of Tumor-Draining Lymph Nodes in Breast Cancer
- Principal Investigator
- 2006 – 2011
- Dept. of Defense Era of Hope Scholar Award for Breast Cancer Research
- Immunology, Systems Biology, and Immunotherapy of Breast Cancer
- Principal Investigator
-
- 2001 – 2009
- NIH/NCI R01
- CTLA-4 Inhibition and Autoimmunity in Melanoma
- Subcontractor
- 2003 – 2007
- American Cancer Society Research Award
- Biology of the Graft-vs-Leukemia Response
- Principal Investigator

- 2004 – 2006
- NIH/NCI P01
- Analysis of T Cell Responses in Vaccinated Patients
- Principal Investigator

- 2001 – 2006
- NIH/NCI R01 CA090809
- Characterization of Tumor-Specific T Cells in Melanoma
- Principal Investigator

- 2005 – 2006
- Mary Hewitt Loveless Pilot Project Grant
- Characterization of Disease-specific T Cells from Celiac Sprue Patients
- Principal Investigator

- 2004 – 2006
- Harry J. Lloyd Charitable Trust
- Mechanisms of Lymph Nodes Invasion by Melanoma
- Principal Investigator

- 2003 – 2005
- Stanford Cancer Research Council Award
- In Vivo Turnover Kinetics of Myeloma
- Principal Investigator

- 2003 – 2005
- Stanford OTL Research Incentive Award
- Computational Modeling of T Cell Signal Integration
- Principal Investigator

- 2001 – 2004
- Damon Runyon Scholar Award (Connie and Bob Lurie Scholar)
- Analysis and Manipulation of the T Cell Response to Cancer
- Principal Investigator

- 2001 – 2004
- FDA H22816 (PI – Dr. Jeffrey Weber, USC)
- Novel Adjuvants for Peptide-based Melanoma Vaccines
- Subcontractor

- 2001 – 2004
- NIH/NCI R01 (PI – Dr. Jeffrey Weber, USC)
- IL-12 as an Adjuvant for a Melanoma Peptide Vaccine
- Subcontractor

- 2000 – 2001
- Stanford Cancer Research Council Award
- 1999 – 2000
- Stanford OTL Research Incentive Award
- 1997 – 2002
- NIH/NCI Physician Scientist Award (K08 CA72976)
- 1993 – 1994
- Bank of America-Giannini Foundation Fellowship
- 1993 – 1994
- AAAI President's Award

VIII. PUBLICATIONS

Publications (peer-reviewed) over 100 Total

1. Ferraris R, **Lee PP**, and Diamond J. What transport adaptations enable mammals to absorb sugars and amino acids faster than reptiles? American Journal of Physiology 249: G271-G283, 1985.
2. Koziol JA, **Lee PP**, Dillman RO, Fagnani R, and Halpern SE. Pharmacokinetics of ¹¹¹In-labelled monoclonal antibody ZCE-025 and fragments in tumour-bearing mice. Nuclear Medicine Communications 16: 299-305, 1995.
3. **Lee PP**, Ramanathan M, Hunt A, and Garovoy MR. An Oligonucleotide Blocks Interferon-Gamma Signal Transduction. Transplantation 62(9):1297-1301, 1996.
4. **Lee PP**, Zeng D, MaCaulay AE, Chen YF, Geiler C, Umetsu DT, and Chao NJ. T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood 90(4):1611-1617, 1997.
5. Yee C, Savage PA, **Lee PP**, Davis MM, and Greenberg PD. Isolation of high-avidity melanoma-reactive CTL from heterogenous populations using peptide-MHC tetramers. Journal of Immunology 162(4):2227-2234, 1999.
6. Molldrem JJ, **Lee PP**, Wang C, Champlin RE, and Davis MM. A HLA-A2-PR1 tetramer can be used to isolate low-frequency CTL from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Research, 59(11):2675-2681, 1999.
7. **Lee PP**, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, and Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Medicine, 5(6):677-685, 1999.
8. Hernandez J, **Lee PP**, Davis MM, and Sherman LA. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self-tolerance on the T cell receptor repertoire. Journal of Immunology 164(2):596-602, 2000.

9. Molldrem JJ, **Lee PP**, Wang C, Felio K, Kantarjian HM, Champlin RE, and Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine, 6(8):1018-1023, 2000.
10. Yee C, Thompson JA, Roche P, Byrd DR, **Lee PP**, Piepkorn M, Kenyon K, Davis MM, Riddell, SR, and Greenberg PD. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. Journal of Experimental Medicine, 192(11):1637-1644, 2000. PMCID: PMC2193107
11. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, **Lee PP**, Schuler G, Knop J, and Enk AH. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. International Journal of Cancer, 93(2):243-51, 2001.
12. **Lee PP**, Wang F, Kuniyoshi J, Rubio V, Stuge T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, and Weber J. Effects of Interleukin-12 on the immune response to a multi-peptide vaccine for resected metastatic melanoma. Journal of Clinical Oncology, 19(7):3836-3847, 2001.
13. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lysterly HK, **Lee PP**, Storkus W, Marincola F, Worobec A, and Atkins MB. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the society for biological therapy. J Immunotherapy 25(2):97-138, 2002.
14. Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, **Lee PP**, Geiger JD, and Mule JJ. A Phase I Trial of Tumor Lysate-pulsed Dendritic Cells in the Treatment of Advanced Cancer. Clin Cancer Res 8(4):1021-1032, 2002.
15. Falco DA, Nepomuceno RR, Krams SM, **Lee PP**, Davis MM, Salvatierra O, Alexander SR, Esquivel CO, Cox KL, Frankel LR, Martinez OM. Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation 74(4):501-510, 2002.
16. Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, and **Lee PP**. Granulocyte-macrophage-colony-stimulating factor added to a multi-peptide vaccine for resected Stage II melanoma. Cancer 97(1):186-200, 2003.
17. Molldrem JJ, **Lee PP**, Kant S, Wieder E, Jiang W, Lu S, Wang C, and Davis MM. Chronic Myelogenous Leukemia Shapes Host Immunity by Selective Deletion of High Avidity Leukemia-Specific T Cells. Journal of Clinical Investigation 111:639-647, 2003. PMCID: PMC151894
18. Chang T, Chang C, Simpson D, Xu Q, Martin P, Lagenaur L, Schoolnik G, Ho D, Hillier S, Holodniy M, Lewicki J, and **Lee PP**. Inhibition of HIV Infectivity by a natural human isolate of *Lactobacillus jensenii* engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A 100(20):11672-11677, 2003. PMCID: PMC208816
19. Pullarkat V, **Lee PP**, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS. A phase I trial of SD-9427 (progenipointin) with a multi-peptide vaccine for resected metastatic melanoma. Clin Cancer Res. Apr;9(4):1301-12, 2003.

20. Tagawa ST, **Lee P**, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 98(1):144-54, 2003.
21. Rubio V, Stuge T, Singh N, Betts M, Weber J, Roederer M, and **Lee PP**. Ex Vivo Identification, Isolation, and Analysis of Tumor-Cytolytic T cells. Nature Medicine 9(11):1377-1382, 2003.
22. Xu T, Shu CT, Purdom E, Dang D, Ilsley D, Guo Y, Weber J, Holmes SP, **Lee PP**. Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in melanoma patients and healthy donors. Cancer Res. 64(10):3661-7, 2004.
23. Chiong B, Wong R, **Lee P**, Delto J, Scotland R, Lau R, Weber J. Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine. J Immunother. 27(5):368-79, 2004.
24. Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber J, and **Lee PP**. Diversity and Recognition Efficiency of T Cell Responses to Cancer. PLoS Med 1(2): e28, 2004. PMCID: PMC529423
25. Sanderson K, Scotland R, **Lee P**, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma. J Clin Oncol. 23(4):741-50, 2005.
26. DeConde R, Kim PS, Levy D, and **Lee PP**. Post-Transplantation Dynamics of the Immune Response to Chronic Myelogenous Leukemia. J Theor Biol. 236(1):39-59, 2005.
27. Holmes SP, He M, Xu T, and **Lee PP**. Memory T cells have gene expression patterns intermediate between naive and effector Proc Natl Acad Sci U S A 102(15):5519-23, 2005. PMCID: PMC556264
28. Casal A, Alber M, Sumen C, Reddy T, and **Lee PP**. Agent-Based Modeling of the Context Dependency in T Cell Recognition. J Theor Biol. 236(4):376-91, 2005.
29. Kohrt HB, Shu CT, Stuge TB, Holmes SP, Weber J, and **Lee PP**. Rapid Assessment of Recognition Efficiency and Functional Capacity of Antigen-Specific T Cell Responses. J Immunother. 28(4):297-305, 2005.
30. Chen D, Soen Y, Stuge TB, **Lee PP**, Weber J, Brown PO, and Davis MM. Marked Differences in Human Melanoma Antigen-Specific T Cell Responsiveness After Vaccination Using a Functional Microarray. PLoS Med. 2(10):e265, 2005. PMCID: PMC1216330
31. Kohrt HB, Nouri N, Nowels K, Johnson D, Holmes SP, and **Lee PP**. Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-free Survival in Breast Cancer. PLoS Med. 2(9):e284, 2005. PMCID: PMC1198041
32. Siegel M, Bethune MT, Gass J, Ehren J, Xia J, Johannsen A, Stuge TB, Gray GM, **Lee PP**, and Khosla C. Rational Design of Combination Enzyme Therapy for Celiac Sprue. Chem Biol. 13(6):649-58, 2006.

33. Liu X, Lagenaur L, Simpson D, Essenmacher K, Frazier-Parker C, Liu Y, Tsai D, Rao S, Hamer D, Parks T, **Lee PP**, Xu Q. Engineered Vaginal Lactobacillus for Mucosal Delivery of the HIV Inhibitor, Cyanovirin-N. Antimicrob Agents Chemother. 50(10):3250-9, 2006. PMCID: PMC1610104
34. Kim PS, **Lee PP**, Levy D. Modeling regulation mechanisms in the immune system. J Theor Biol 246(1):33-69, 2007.
35. Nacu S, Critchley-Thorne R, **Lee P**, Holmes S. Gene expression network analysis and applications to immunology. Bioinformatics 23(7):850-8, 2007.
36. Kapelner A, **Lee PP**, Holmes S. An Interactive Statistical Image Segmentation and Visualization System. Medivis (IEEE Computer Society) 0: 81–86, 2007.
37. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, and **Lee PP**. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4(5):e176, 2007. PMCID: PMC1865558
38. Kim PS, **Lee PP**, Levy D. Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models. Bull Math Biol 2008 Apr;70(3):728-44.
39. Chen CI, Maecker HT, **Lee PP**. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 2008 Jun 1;111(11):5342-9. PMCID: PMC2396727
40. Kim PS, **Lee PP**, Levy D. Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput Biol 2008 Jun 20;4(6):e1000095. (*co-corresponding author) PMCID: PMC2427197
41. Liu X, Lagenaur LA, **Lee PP**, Xu Q. Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules. Appl Environ Microbiol 2008 Aug;74(15):4626-35. PMCID: PMC2504410
42. Kim PS, **Lee PP**, Levy D. A PDE model for imatinib-treated chronic myelogenous leukemia. Bull Math Biol 2008 Oct;70(7):1994-2016.
43. Butterfield LH, Disis ML, Fox BA, **Lee PP**, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Hakansson L, Janetzki S, Kleen TO, Kirkwood J, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stronck DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM. A systematic approach to biomarker discovery; Preamble to the iSBTc-FDA taskforce on Immunotherapy Biomarkers. J Transl Med 2008 Dec 23;6(1):81. PMCID: PMC2630944
44. Holmes S, Kapelner A, **Lee PP**. An Interactive Java Statistical Image Segmentation System: GemIdent. Journal of Statistical Software 2009 Jan 15;30(10):1-20. PMCID: PMC3100170
45. Yu RR, Cheng AT, Lagenaur LA, Huang W, Weiss DE, Treece J, Sanders-Beer BE, Hamer DH, **Lee PP**, Xu Q, Liu Y. A Chinese rhesus macaque (*Macaca mulatta*) model for vaginal Lactobacillus colonization and live microbicide development. J Med Primatol. 2009 Apr;38(2):125-36. PMCID: PMC4422182

46. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, Swetter SM, Carlson RW, Fisher GA, Koong A, Holmes S, **Lee PP**. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9010-5. PMID: PMC2690021
47. Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, **Lee PP**, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkühle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med. 2009 Jun 17;7:45. PMID: PMC2724494
48. Kohrt H, Johannsen A, Hoppe R, Horning SJ, Rosenberg SA, Advani R, **Lee PP**. Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease. Oncol Res. 2009;18(5-6):287-92. PMID: PMC5568662
49. Niculescu SI, Kim PS, Gu K, **Lee PP**, Levy D. Stability Crossing Boundaries of Delay Systems Modeling Immune Dynamics in Leukemia. Discrete and Continuous Dynamical Systems B, 2010; 13:129-156.
50. Kim PS, **Lee PP**, Levy D. Emergent group dynamics governed by regulatory cells produce a robust primary T cell response. Bull Math Biol. 2010 Apr;72(3):611-44. PMID: PMC3008572
51. Setiadi AF, Ray NC, Kohrt HE, Kapelner A, Carcamo-Cavazos V, Levic EB, Yadegarynia S, van der Loos C, Schwartz EJ, Holmes SP, and **Lee PP**. Quantitative, Architectural Analysis of Immune Cell Subsets in Tumor-Draining Lymph Nodes from Breast Cancer Patients and Healthy Lymph Nodes. PLoS ONE 2010, 5(8): e12420. doi:10.1371/journal.pone.0012420. PMID: PMC2928294
52. Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, **Lee PP**, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011 Mar 26;9:32. PMID: PMC3078100
53. Kim PS and **Lee PP**. T cell state transition produces an emergent change detector. J Theor Biol. 2011 Apr 21;275(1):59-69. P. PMID: PMC3050581
54. Paquin D, Kim PS, **Lee PP**, Levy D. Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia. Bull Math Biol. 2011 May;73(5):1082-100. doi: 10.1007/s11538-010-9553-0. PMID: PMC3862185
55. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, **Lee PP**, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML. Recommendations from the iSBTC-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res. 2011 May 15;17(10):3064-76. PMID: PMC3096674

56. Simons DL, Lee G, Kirkwood JM, **Lee PP**. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med. 2011 May 5;9:52. PMID: PMC3114759
57. Chang GY, Kohrt HE, Stuge TB, Schwartz EJ, Weber JS, **Lee PP**. Cytotoxic T lymphocyte responses against melanocytes and melanoma. J Transl Med. 2011 Jul 27;9(1):122. PMID: PMC3158754
58. Kim PS, **Lee PP**, Levy D. A Theory of Immunodominance and Adaptive Regulation. Bull Math Biol. 2011 Jul;73(7):1645-65. doi: 10.1007/s11538-010-9585-5. PMID: PMC3865720
59. Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, Liu Y, Yu R, Venzon D, **Lee PP**, Hamer DH. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol. 2011 Nov;4(6):648-57. doi: 10.1038/mi.2011.30. PMID: PMC3433722
60. Liu X, Setiadi AF, Alber MS, Lee PP, Chen DZ. Identification and classification of cells in multispectral microscopy images of lymph nodes. SPIE (International Society for Optics and Photonics) Medical Imaging Annual Conference, 2011. doi: 10.1117/12.878399.
61. Lagenaur LA, Lee PP, Hamer DH, Sanders-Beer BE. Demonstration of vaginal colonization with GusA-expressing Lactobacillus jensenii following oral delivery in rhesus macaques. Res Microbiol. 2011 Dec;162(10):1006-10. doi: 10.1016/j.resmic.2011.08.003. Epub 2011 Aug 29. PubMed PMID: 21907793; PubMed Central PMCID: PMC3449312.
62. Kim PS and **Lee PP**. Modeling Protective Anti-Tumor Immunity via Preventative Cancer Vaccines Using a Hybrid Agent-based and Delay Differential Equation Approach. PLoS Comput Biol. 2012 Oct;8(10):e1002742. PMID: PMC370557
63. Yu HX, Simons DL, Carcamo-Cavazos V, Schwartz EJ, Yan N, Zuckerman N, Segal I, Dirbas FM, Johnson DL, Holmes SP, and **Lee PP**. PRC2/EED-EZH2 Complex Is Up-regulated in Breast Cancer Lymph Node Metastasis Compared to Primary Tumor and Correlates with Tumor Proliferation In Situ. PLoS ONE, PLoS One. 2012;7(12):e51239. doi: 10.1371/journal.pone.0051239. PMID: PMC3486888
64. Zuckerman NS, Noam Y, Goldsmith AJ, and **Lee PP**. A self-directed method for cell-type identification and separation of gene expression microarrays. PLoS Comp Biol, 2013;9(8):e1003189. doi: 10.1371/journal.pcbi.1003189. PMID: PMC3749952
65. Zuckerman NS, Yu H, Simons DL, Bhattacharya N, Carcamo-Cavazos V, Yan N, Dirbas FM, Johnson DL, Schwartz EJ, and **Lee PP**. Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients. Int J Cancer 2013 Jun 1;132(11):2537-47. doi: 10.1002/ijc.27933. PMID: PMC3609917
66. Chang AY, Bhattacharya N, Mu J, Setiadi AF, Carcamo-Cavazos V, Lee GH, Simons DL, Yadegarynia S, Hemati K, Kapelner A, Ming Z, Krag DN, Schwartz EJ, Chen DZ, **Lee PP**. Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients. J Transl Med. 2013 Oct 2;11:241. PMID: PMC3852260

67. Brichacek B, Lagenaur LA, **Lee PP**, Venzon D, Hamer DH. In vivo evaluation of safety and toxicity of a *Lactobacillus jensenii* producing modified cyanovirin-N in a rhesus macaque vaginal challenge model. PLoS One. 2013 Nov 12;8(11):e78817. PMID: PMC3827103
68. Cereghetti DM and **Lee PP**. Tumor-Derived Exosomes Contain microRNAs with Immunological Function: Implications for a Novel Immunosuppression Mechanism. MicroRNA Journal 2014 2(3):194-204.
69. Liu Q, Tomei S, Ascierto ML, De Giorgi V, Bedognetti D, Dai C, Uccellini L, Spivey T, Pos Z, Thomas J, Reinboth J, Murtas D, Zhang Q, Chouchane L, Weiss GR, Slingsluff CL Jr, **Lee PP**, Rosenberg SA, Alter H, Yao K, Wang E, Marincola FM. Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest. 2014 Apr 1. PMID: PMC4001531
70. Riess JW, Bhattacharya N, Blenman KR, Neal JW, Hwang G, Pultar P, San-Pedro Salcedo M, Engleman E, **Lee PP**, Malik R, Wakelee HA. Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacol Immunotoxicol. 2014 Apr;36(2):182-6. PMID: PMC6464638
71. Chung B, Stuge TB, Murad JP, Beilhack G, Andersen E, Armstrong BD, Weber JS, and **Lee PP**. Antigen-Specific Inhibition of High-Avidity T Cell Target Lysis by Low-Avidity T Cells via Trogocytosis. Cell Reports 2014 Aug 7;8(3):871-82. PMID: PMC4174572
72. Blenman KR, **Lee PP**. Quantitative and spatial image analysis of tumor and draining lymph nodes using immunohistochemistry and high-resolution multispectral imaging to predict metastasis. Methods Mol Biol. 2014;1102:601-21. PMID: 24259001
73. Lagenaur LA, Swedek I, **Lee PP**, Parks TP. Robust Vaginal Colonization of Macaques with a Novel Vaginally Disintegrating Tablet Containing a Live Biotherapeutic Product to Prevent HIV Infection in Women. PLoS One 2015 Apr 14;10(4). PMID: PMC4397015
74. Xu Y, Wu W, Chang EI, Chen D, Mu J, **Lee PP**, Blenman KR, Tu Z. A two-layer structure prediction framework for microscopy cell detection. Comput Med Imaging Graph. 2015 Apr;41:29-36. PMID: 25082065
75. Draganov D, Gopalakrishna-Pillai S, Chen YR, Zuckerman N, Moeller S, Wang C, Ann D, and **Lee PP**. Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death. Sci Rep, 2015 Nov 10;5:16222. PMID: PMC4639773
76. Stack EC, Foukas PG, **Lee PP**. Multiplexed tissue biomarker imaging. J Immunother Cancer. 2016 Feb 16;4:9. PMID: PMC4754920
77. Marcobal A, Liu X, Zhang W, Dimitrov AS, Jia L, **Lee PP**, Fouts TR, Parks TP, Lagenaur LA. Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal *Lactobacillus*. AIDS Res Hum Retroviruses. 2016 Apr 13. PMID: PMC5067876
78. Munson DJ, Egelston CA, Chiotti KE, Parra ZE, Bruno TC, Moore BL, Nakano TA, Simons DL, Jimenez G, Yim JH, Rozanov DV, Falta MT, Fontenot AP, Reynolds PR, Leach SM, Borges VF, Kappler JW, Spellman PT, **Lee PP**, Slansky JE. Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8272-7. PMID: PMC4961128

79. Wang L, Miyahira AK, Simons D, Lu X, Chang A, Wang C, Suni M, Maino VC, Dirbas FM, Yim JH, Waisman J, and **Lee PP**. IL-6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer. Cancer Res. 2016 Nov 22. PMID: PMC5334262
80. Gong J, Wang C, **Lee PP**, Chu P, Fakih M. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a *POLE* Mutation. J Natl Compr Canc Netw 2017 Feb;15(2): 142-147. PMID: 28188185
81. Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, **Lee PP**, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B. Systematic evaluation of immune regulation and modulation. J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. PMID: PMC5359947
82. Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, **Lee PP**, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH. Immunotherapy biomarkers 2016: overcoming the barriers. J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6. PMID: PMC5359902
83. Chung B, Gopalakrishna-Pillai S, Esmali A, Waisman J, Badie B, and **Lee PP**. Human brain metastatic stroma attracts breast cancer cells via chemokines CXCL16 and CXCL12. NPJ Breast Cancer. 2017 Mar 2;3:6. doi: 10.1038/s41523-017-0008-8. eCollection 2017. PMID: PMC5460196
84. Li X, Balagam R, He TF, **Lee PP**, Igoshin OA, Levine H. On the mechanism of long-range orientational order of fibroblasts. Proc Natl Acad Sci U.S.A. 2017 Aug 22. PMID: PMC5576822
85. Rozanov DV, Rozanov ND, Chiotti KE, Reddy A, Wilmarth PA, David LL, Cha SW, Woo S, Pevzner P, Bafna V, Burrows GG, Rantala JK, Levin T, Anur P, Johnson-Camacho K, Tabatabaei S, Munson DJ, Bruno TC, Slansky JE, Kappeler JW, Hirano N, Boegel S, Fox BA, Egelston C, Simons DL, Jimenez G, **Lee PP**, Gray JW, Spellman PT. MHC class I loaded ligands from breast cancer cell lines. A potential HLA-I-typed antigen collection. J Proteomics. 2018 Mar 30, 176:13-23. PMID: PMC5999401
86. Wang C, Gong J, Tu TY, **Lee PP**, Fakih, M. Immune profiling of microsatellite instability-high and polymerase ε (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. J Gastrointest Oncol. 2018 Jun;9(3): 404-415. PMID: PMC6006042
87. Blenman KRM, He TF, Frankel PH, Ruel NH, Schwartz EJ, Krag DN, Tan LK, Yim JH, Mortimer JE, Yuan Y, **Lee PP**. Sentinel lymph node B cells can predict disease-free survival in breast cancer patients. NPJ Breast Cancer 2018 Aug 23;4:28. PMID: PMC6107630
88. Poultsidi A, Dimopoulos Y, He TF, Chavakis T, Saloustros E, **Lee PP**, Petrovas C. Lymph node Cellular Dynamics in Cancer and HIV: What can we learn for the Follicular CD4 (Tfh) Cells? Front Immunol 2018 Sep 27;9:2233. PMID: PMC6170630
89. Egelston CA, Avalos C, Tu TY, Simons DL, Jimenez G, Jung JY, Melstrom L, Margolin K, Yim JH, Kruper L, Mortimer J, **Lee PP**. Human Breast tumor-infiltrating CD8[±]T cells retain polyfunctionality despite PD-1 expression. Nat Commun. 2018 Oct 16; 9(1):4297. PMID: PMC6191461

90. Utama R, Bastian A, Sadagopan N, Jin Y, Antoniou E, Gao Q, Huang YJ, Pillai S, **Lee PP**, Atwal GS. Cell non-autonomous interactions during non-immune stromal progression in the breast tumor microenvironment. BioRxiv. 2019 February. Doi: 10.1101/540112
91. Jung EE, Heinemann FS, Egelston CA, Wang J, Pollock RE, **Lee PP**, Tseng WW. Synchronous recurrence of concurrent colon adenocarcinoma and dedifferentiated liposarcoma. BMJ Case Rep. 2019 May 13;12(5). pii: e228868. doi: 10.1136/bcr-2018-228868. PMCID: PMC6536183
92. Wang L, Simons DL, Lu X, Tu TT, Solomon S, Wang R, Rosario A, Avalos C, Schmolze D, Yim J, Waisman J, **Lee PP**. Connecting Blood and intratumoral T_{reg} cell activity in predicting future relapse in breast cancer. Nature Immunology. 2019 July. Doi: 10.1038/s41590-019-0429-7. PMID: 31285626 PMCID: PMC8802768
93. Fakih M, Ouyang C, Wang C, Tu TY, Gozo MC, Cho M, Sy M, Longmate JA, **Lee PP**. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. J Clin Invest. 2019 Oct 1;129(10):4464-4476. Doi: 10.1172/JCI127046. PMCID: PMC6763253
94. Egelston CA, Avalos C, Tu TY, Rosario A, Wang R, Solomon S, Srinivasan G, Nelson MS, Huang Y, Lim MH, Simons DL, He TF, Yim JH, Kruper L, Mortimer J, Yost S, Guo W, Ruel C, Frankel PH, Yuan Y, **Lee PP**. Resident memory CD8⁺ T cells within cancer islands mediate survival in breast cancer patients. JCI Insight 2019 Oct 3, 4(19). Pii: 130000. Doi: 10.1172/jci.insight. PMCID: PMC6795408
95. Zhang C, Yue C, Herrmann A, Song J, Egelston C, Wang T, Zhang Z, Li W, Lee H, Aftabizadeh M, Li YJ, **Lee PP**, Forman S, Somlo G, Chu P, Kruper L, Mortimer J, Hoon DSB, Huang W, Priceman S, Yu H. STAT3 Activation-Induced Fatty Acid Oxidation in CD8⁺ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth. Cell Metab. 2020 Jan 7;31(1):148-161.e5. doi: 10.1016/j.cmet.2019.10.013. Epub 2019 Nov 21. PMID: 31761565 PMCID: PMC6949402
96. Kumbhari A, Kim PS, **Lee PP**. Optimisation of anti-cancer peptide vaccines to preferentially elicit high-avidity T cells. J Theor Biol. 2020 Feb 7;486:110067. doi: 10.1016/j.jtbi.2019.110067. Epub 2019 Nov 6. PMID: 31704311
97. Kalvala A, Wallet P, Yang L, Wang C, Li H, Nam A, Nathan A, Mambetsariev I, Poroyko V, Gao H, Chu P, Sattler M, Bild A, Manuel ER, **Lee PP**, Jolly MK, Kulkarni P, Salgia R. Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. J Clin Med. 2019 Oct 18;8(10). Pii: E1726. Doi: 10.3390/jcm8101726. PMCID: PMC6832522
98. Wang C, Park J, Ouyang C, Longmate JA, Tajon M, Chao J, Lim D, Sandhu J, Yin HH, Pillai R, Gozo MC, Avalos C, Egelston CA, **Lee PP**, Fakih M. A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases. Oncologist. 2020 May;25(5):382-e776. doi: 10.1634/theoncologist.2019-0924. Epub 2019 Dec 19. PMID: 31857446 PMCID: PMC7216435
99. Wang L, Simons DL, Lu X, Tu TY, Avalos C, Chang AY, Dirbas FM, Yim JH, Waisman J, **Lee PP**. Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes. EBioMedicine. 2020 Feb;52:102631. doi: 10.1016/j.ebiom.2020.102631. Epub 2020 Jan 22. PMID: 31981982 PMCID: PMC6992943

100. Wang L, **Lee PP**. Systemic Correlates of the Tumor Microenvironment. Cancer Treat Res. 2020;180:97-109. doi: 10.1007/978-3-030-38862-1_3. PMID: 32215867
101. Lindner SE, Egelston CA, Huard SM, **Lee PP**, and Wang LD. Arhgap25 deficiency leads to decreased numbers of peripheral blood B cells and defective germinal center reactions. Immunohorizons. 2020 May 20;4(5):274-281. doi: 10.4049/immunohorizons.2000021. PMCID: PMC7301639
102. Le J, Park JE, Ha VL, Luong A, Branciamore S, Rodin AS, Gogoshin G, Li F, Loh YE, Camacho V, Patel SB, Welner RS, Parekh C. Single-Cell RNA-Seq Mapping of Human Thymopoiesis Reveals Lineage Specification Trajectories and a Commitment Spectrum in T Cell Development. Immunity. 2020 Jun 16;52(6):1105-1118.e9. doi: 10.1016/j.immuni.2020.05.010. PubMed PMID: 32553173; PubMed Central PMCID: PMC7388724.
103. Wang X, Branciamore S, Gogoshin G, Ding S, Rodin AS. New Analysis Framework Incorporating Mixed Mutual Information and Scalable Bayesian Networks for Multimodal High Dimensional Genomic and Epigenomic Cancer Data. Front Genet. 2020;11:648. doi: 10.3389/fgene.2020.00648. eCollection 2020. PubMed PMID: 32625238; PubMed Central PMCID: PMC7314938.
104. Zhao D, Mambetsariev I, Li H, Chen C, Fricke J, Fann P, Kulkarni P, Xing Y, **Lee PP**, Bild A, Massarelli E, Koczywas M, Reckamp K, Salgia R. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer. 2020 Aug;146:174-181. doi: 10.1016/j.lungcan.2020.05.025. Epub 2020 May 24. PMID: 32554069 PMCID: PMC8158847
105. Schibber EF, Mittelstein DR, Gharib M, Shapiro MG, **Lee PP**, Ortiz M. A dynamical model of oncotripsy by mechanical cell fatigue: selective cancer cell ablation by low-intensity pulsed ultrasound. Proc Math Phys Eng Sci. 2020 Apr;476(2236):20190692. doi: 10.1098/rspa.2019.0692. Epub 2020 Apr 29. PMID: 32398930 PMCID: PMC7209139.
106. Yu G, Li X, He TF, Gruosso T, Zuo D, Souleimanova M, Ramos VM, Omeroglu A, Meterissian S, Guiot MC, Yang L, Yuan Y, Park M, **Lee PP**, Levine H. Predicting Relapse in Patients With Triple Negative Breast Cancer (TNBC) Using a Deep-Learning Approach. Front Physiol. 2020 Sep 23;11:511071. doi: 10.3389/fphys.2020.511071. eCollection 2020. PMID: 33071806 PMCID: PMC7538858
107. Kumbhari A, Egelston CA, **Lee PP**, Kim PS. Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses. Front Immunol. 2020 Oct 30;11:584680. doi: 10.3389/fimmu.2020.584680. eCollection 2020. PMID: 33193401 PMCID: PMC7662095.
108. Wortman JC, He TF, Solomon S, Zhang RZ, Rosario A, Wang R, Tu TY, Schmolze D, Yuan Y, Yost SE, Li X, Levine H, Atwal G, **Lee PP**,* Yu CC.* Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome. NPJ Breast Cancer. 2021 Jul 1;7(1):84. doi: 10.1038/s41523-021-00291-z. PubMed PMID: 34210991 PMCID: PMC8249408. (*co-corresponding authors)
109. Draganov D, **Lee PP**. Purinergic Signaling Within the Tumor Microenvironment. Adv Exp Med Biol. 2021;1270:73-87. doi: 10.1007/978-3-030-47189-7_5. PMID: 33123994
110. Karolak A, Branciamore S, McCune JS, **Lee PP**, Rodin AS, Rockne RC. Concepts and Applications of Information Theory to Immuno-Oncology. Trends Cancer. 2021 Apr;7(4):335-346. doi: 10.1016/j.trecan.2020.12.013. Epub 2021 Feb 20. PMID: 33618998 PMCID: PMC8156485

111. Chen J, Cao X, Li B, Zhao Z, Chen S, Lai SWT, Muend SA, Nossa GK, Wang L, Guo W, Ye J, **Lee PP**, Feng M. Warburg Effect Is a Cancer Immune Evasion Mechanism Against Macrophage Immunosurveillance. Front Immunol. 2021 Feb 2;11:621757. doi: 10.3389/fimmu.2020.621757. eCollection 2020. PMID: 33603751 PMCID: PMC7884830
112. Rodin AS, Gogoshin G, Hilliard S, Wang L, Egelston C, Rockne RC, Chao J, **Lee PP**. Dissecting Response to Cancer Immunotherapy by Applying Bayesian Network Analysis to Flow Cytometry Data. Int J Mol Sci. 2021 Feb 26;22(5):2316. doi: 10.3390/ijms22052316. PMID: 33652558 PMCID: PMC7956201
113. Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Gillece JD, Folkerts M, Reining L, Highlander SK, Robinson K, Padam S, Martinez N, Tang A, Schmolze D, Waisman J, Sedrak M, **Lee PP**, Mortimer J. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. Oncologist. 2021 Feb;26(2):99-e217. doi: 10.1002/onco.13583. Epub 2020 Nov 24. PMID: 33141975 PMCID: PMC7873338
114. Yu CC, Wortman JC, He TF, Solomon S, Zhang RZ, Rosario A, Wang R, Tu TY, Schmolze D, Yuan Y, Yost SE, Li X, Levine H, Atwal G, **Lee PP**. Physics approaches to the spatial distribution of immune cells in tumors. Rep Prog Phys. 2021 Feb;84(2):022601. doi: 10.1088/1361-6633/abcd7b. PMID: 33232952
115. Kumbhari A, Rose D, **Lee PP**, Kim PS. A minimal model of T cell avidity may identify subtherapeutic vaccine schedules. Math Biosci. 2021 Apr;334:108556. doi: 10.1016/j.mbs.2021.108556. Epub 2021 Feb 2. PMID: 33539903
116. Egelston C, Guo W, Yost S, Lee JS, Rose D, Avalos C, Ye J, Frankel P, Schmolze D, Waisman J, **Lee P**, Yuan Y. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer. J Immunother Cancer. 2021 Mar;9(3):e002084. doi: 10.1136/jitc-2020-002084. PMID: 33757987; PMCID: PMC7993344.
117. Draganov D, Han Z, Rana A, Bennett N, Irvine DJ, **Lee PP**. Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Breast Cancer. 2021 Mar 2;7(1):22. doi: 10.1038/s41523-021-00229-5. PMID: 33654071 PMCID: PMC7925581
118. Lagenaur LA, Hemmerling A, Chiu C, Miller S, **Lee PP**, Cohen CR, Parks TP. Connecting the Dots: Translating the Vaginal Microbiome Into a Drug. J Infect Dis. 2021 Jun 16;223(12 Suppl 2):S296-S306. doi: 10.1093/infdis/jiaa676. PMID: 33330916; PMCID: PMC8502429.
119. Wang C, Sandhu J, Ouyang C, Ye J, **Lee PP**, Fakhri M. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. JAMA Netw Open. 2021 Aug 2;4(8):e2118416. doi: 10.1001/jamanetworkopen.2021.18416. PMID: 34369992; PMCID: PMC8353537.
120. Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Padam S, Tang A, Martinez N, Schmolze D, Presant C, Ebrahimi B, Yeon C, Sedrak M, Patel N, Portnow J, **Lee P**, Mortimer J. Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. Eur J Cancer. 2021 Sep;154:11-20. doi: 10.1016/j.ejca.2021.05.035. Epub 2021 Jul 1. PMID: 34217908; PMCID: PMC8691850.
121. Chao J, He TF, D'Apuzzo M, Chen YJ, Frankel P, Tajon M, Chen H, Solomon S, Klempner SJ, Fakhri M, **Lee P**. A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment

Abscopal Immune Responses. *Adv Radiat Oncol*. 2021 Sep 14;7(1):100807. doi: 10.1016/j.adro.2021.100807. PMID: 35071830; PMCID: PMC8767243.

122. Egelston CA, Guo W, Tan J, Avalos C, Simons DL, Lim MH, Huang YJ, Nelson MS, Chowdhury A, Schmolze DB, Yim JH, Kruper L, Melstrom L, Margolin K, Mortimer JE, Yuan Y, Waisman JR, **Lee PP**. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-positive breast cancer. *JCI Insight*. 2022 Feb 8;7(3). doi: 10.1172/jci.insight.153963. PMID: 35132960.
123. Ye J, **Lee PP**. B cell receptor signaling strength modulates cancer immunity. *J Clin Invest*. 2022 Mar 15;132(6):e157665. doi: 10.1172/JCI157665. PMID: 35289309; PMCID: PMC8920327.
124. Rodin AS, Uduman M, **Lee PP**, Marincola FM, Branciamore S. Editorial: Systems Biology Methods in Computational Immuno-Oncology. *Front Genet*. 2022 Apr 8;13:885252. doi: 10.3389/fgene.2022.885252. PMID: 35464864; PMCID: PMC9024133.
125. Dellinger TH, Han ES, Raoof M, Lee B, Wu X, Cho H, He TF, **Lee P**, Razavi M, Liang WS, Schmolze D, Priceman SJ, Lee S, Lin WC, Lin JF, Kebria M, Hakim A, Ruel N, Stewart DB, Wang EW, Paz BI, Wakabayashi MT, Cristea MC, Rodriguez-Rodriguez L. Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer. *JCO Precis Oncol*. 2022 Mar;6:e2100239. doi: 10.1200/PO.21.00239. Erratum in: *JCO Precis Oncol*. 2022 Jun;6:e2200296. PMID: 35357903; PMCID: PMC8984280.
126. Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KJ, Armenian S, Nwangwu M, **Lee PP**, Zain J, Nikolaenko L, Popplewell L, Nademane A, Chaudhry A, Rosen S, Kwak L, Forman SJ, Herrera AF. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. *Blood*. 2022 Jun 23;139(25):3605-3616. doi: 10.1182/blood.2022015423. PMID: 35316328; PMCID: PMC9227101.
127. Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, Jonsson VD, Zarif JC, **Lee PP**, Wang X, Martinez C, Dorff TB, Forman SJ, Priceman SJ. PD-L1 blockade restores CAR T cell activity through IFN- γ -regulation of CD163+ M2 macrophages. *J Immunother Cancer*. 2022 Jun;10(6):e004400. doi: 10.1136/jitc-2021-004400. PMID: 35738799; PMCID: PMC9226933.
128. Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademane A, Puverel S, Nwangwu M, **Lee P**, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. *Lancet Haematol*. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17. PMID: 36403579.
129. Song JY, Nwangwu M, He TF, Zhang W, Meawad H, Bedell V, Murata-Collins J, Skrabek P, Nasr MR, Scott D, Godfrey J, **Lee P**, Chan WC, Weisenburger DD, Perry AM, Herrera AF. Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma. *Haematologica*. 2023 Aug 1;108(8):2167-2177. doi: 10.3324/haematol.2022.282265. PMID: 36632739.

130. Hilliard S, Mosoyan K, Branciamore S, Gogoshin G, Zhang A, Simons DL, Rockne RC, **Lee PP**, Rodin AS. Bow-tie architectures in biological and artificial neural networks: Implications for network evolution and assay design. iScience. 2023 Jan 25;26(2):106041. doi: 10.1016/j.isci.2023.106041. PMID: 36818303; PMCID: PMC9929672.
131. Bayar E, MacIntyre DA, Sykes L, Mountain K, Parks TP, **Lee PP**, Bennett PR. Safety, tolerability, and acceptability of *Lactobacillus crispatus* CTV-05 (LACTIN-V) in pregnant women at high-risk of preterm birth. Benef Microbes. 2023 Mar 14;14(1):45-55. doi: 10.3920/BM2022.0084. Epub 2023 Feb 23. PMID: 36815494
132. Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, Tang A, Martinez N, Karimi M, Somlo G, **Lee PP**, Waisman JR, Yuan Y. Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer. Cancer Immunol Immunother. 2023 Sep;72(9):3013-3027. doi: 10.1007/s00262-023-03470-y. Epub 2023 Jun 9. PMID: 37294342, PMCID: PMC10412661.
133. Han Z, Wu X, Qin H, Yuan YC, Schmolze D, Su C, Zain J, Moyal L, Hodak E, Sanchez JF, **Lee PP**, Feng M, Rosen ST, Querfeld C. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma. JCI Insight. 2023 Jul 10;8(13):e163518. doi: 10.1172/jci.insight.163518. PMID: 37427589, PMCID: PMC10371344.
134. Ye J, Guo W, Wang C, Egelston CA, D'Apuzzo M, Shankar G, Fakih MG, **Lee PP**. Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases. Cancer Res Commun. 2023 Oct 12;3(10):2082-2095. doi: 10.1158/2767-9764.CRC-23-0212. PMID: 37768208, PMCID: PMC10569153.
135. Wang L, Guo W, Guo Z, Yu J, Tan J, Simons DL, Hu K, Liu X, Zhou Q, Zheng Y, Colt EA, Yim J, Waisman J, **Lee PP**. PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer. Cell Rep Med. 2024 Feb 20;5(2):101420. doi: 10.1016/j.xcrm.2024.101420. PMID: 38382468, PMCID: PMC10897617.
136. Tan J, Egelston CA, Guo W, Stark JM, **Lee PP**. STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity. EBioMedicine. 2024 Feb 23;101:105035. doi: 10.1016/j.ebiom.2024.105035. Online ahead of print. PMID: 38401418, PMCID: PMC10904200
137. Bacon ER, Ihle K, Guo W, Egelston CA, Simons DL, Wei C, Tumyan L, Schmolze D, **Lee PP**, Waisman JR. Tumor heterogeneity and clinically invisible micrometastases in metastatic breast cancer-a call for enhanced surveillance strategies. NPJ Precis Oncol. 2024 Mar 29;8(1):81. doi: 10.1038/s41698-024-00572-3. PMID: 38553598, PMCID: PMC10980766.
138. Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, Frankel P, Llamas-Quitiquit M, Hsu J, Zengin ZB, Alcantara M, Castro D, Mercier B, Chawla N, Chehrizi-Raffle A, Barragan-Carrillo R, Jaime-Casas S, Govindarajan A, Gillece J, Trent J, **Lee PP**, Parks TP, Takahashi M, Hayashi A, Kortylewski M, Caporaso JG, Lee K, Tripathi A, Pal SK. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2024 Sep;30(9):2576-2585. doi: 10.1038/s41591-024-03086-4. Epub 2024 Jun 28. PMID: 38942995, PMCID: PMC11405272.
139. Egelston CA, Guo W, Simons DL, Ye J, Avalos C, Solomon ST, Nwangwu M, Nelson MS, Tan J, Bacon ER, Ihle K, Schmolze D, Tumyan L, Waisman JR, **Lee PP**. Organ-Specific Immune Setpoints Underlie Divergent Immune

Profiles across Metastatic Sites in Breast Cancer. Cancer Immunol Res. 2024 Nov 4;12(11):1559-1573. doi: 10.1158/2326-6066.CIR-23-0718. PMID: 39051632, PMCID: PMC11534553.

140. Guo W, Tan J, Wang L, Egelston CA, Simons DL, Ochoa A, Lim MH, Wang L, Solomon S, Waisman J, Wei CH, Hoffmann C, Song J, Schmolze D, **Lee PP**. Tumor draining lymph nodes connected to cold triple-negative breast cancers are characterized by Th2-associated microenvironment. Nat Commun. 2024 Oct 4;15(1):8592. doi: 10.1038/s41467-024-52577-y. PMID: 39366933, PMCID: PMC11452381.
141. Orcutt-Jahns B, Lima Junior JR, Lin E, Rockne RC, Matache A, Branciamore S, Hung E, Rodin AS, **Lee PP**, Meyer AS. Systems profiling reveals recurrently dysregulated cytokine signaling responses in ER+ breast cancer patients' blood. NPJ Syst Biol Appl. 2024 Oct 10;10(1):118. doi: 10.1038/s41540-024-00447-0. PMID: 39389979, PMCID: PMC11467214.

Book Chapters

1. Peter P. Lee. T-cell responses to cancer. Methods Cell Biol. 75:513-32, 2004
2. Peter P. Lee. Tetramer Analysis. Handbook of Immune Monitoring, 2005
3. Tom P. Parks, Qiang Xu, Laurel A. Lagenaur, and Peter P. Lee. Bacterial Therapeutics for the Treatment and Prevention of Urogenital Infections. Probiotics and prebiotics: scientific aspects, 2005
4. Peter P. Lee and Francesco Marincola. Peptide-MHC Tetramer Analysis. Analyzing T Cell Responses, 2005
5. Kim PS, Levy D, **Lee PP**. Modeling and simulation of the immune system as a self-regulating network. Methods Enzymol. 2009;467:79-109.
6. Critchley-Thorne RJ, Yu HX, and **Lee PP**. Immune Signatures Associated with the Cancer Bearing State. Immunologic Signatures of Rejection, 2010
7. Blenman KR, **Lee PP**. Quantitative and Dr image analysis of tumor and draining lymph nodes using immunohistochemistry and high-resolution multispectral imaging to predict metastasis. Methods Mol Biol. 2014;1102:601-21.
8. Egelston CA, **Lee PP**. Complexities of the Lung Tumor Microenvironment. Current Cancer Research 2019, 179-194. https://doi.org/10.1007/978-3-030-17832-1_9
9. Wang Lei, **Lee Peter P**. Chapter: Systemic Correlates of the Tumor Microenvironment. Cancer Treatment and Research 2020, 97-109. Editors: Lee, PP and Marincola, FM and Rosen, S., Springer International Publishing
<https://doi.org/10.1007/978-3-030-38862-1>

XI. PATENTS, INVENTIONS AND COPYRIGHTS

PATENTS

- Peter P. Lee. Protection from viral infection via colonization of mucosal membranes with genetically-modified bacteria. US patent #5,733,540 issued 3/31/98
- Peter P. Lee. A method of improving the half-life of soluble viral-specific ligands on mucosal membranes. US patent #6,365,156 B1 issued 4/2/02
- Peter P. Lee. Methods and compositions for identifying target cell cytolytic T cells in a sample. US patent #60/508,709, issued 2/2/06
- Holbrook Kohrt and Peter P. Lee. Immune profile in axillary lymph nodes predicts disease-free survival in breast cancer. US patent #11/509,976 issued 3/1/07
- Tor B. Stuge and Peter P. Lee. Methods for producing target cell reactive lymphocyte. US Patent #7,598,223 issued 10/6/09
- Samuel C. Silverstein, John D. Loike, Sadna Budhu, and Peter P. Lee. Methods, Compositions, and Assays for Determining the Effect of an Immune Cell on a Cell from an Infectious or Neoplastic Disease. U.S. Patent #13/509,405, issued 3/14/13